Venture capital and corporate venturing units stump up $40m for Calistoga Pharmaceuticals' series C round.
Calistoga Pharmaceuticals, a US-based drug developer of cancer treatments backed by Amgen Ventures, has raised $40m in its series C round.
US investment firm Quogue Capital led the C round as a new investor, along with US venture capital firms Alta Partners, Frazier Healthcare, Three Arch Partners, Latterell Venture Partners and Amgen Ventures, the corporate venturing arm of biotechnology company Amgen set up in 2004.
Frazier founded Calistoga Pharmaceuticals in 2006 as a spin out of a drug…
